United States Patent 8,999,638: Iloperidone, KCNQ1 Genotyping, and Patent-Landscape Analysis
U.S. Patent No. 8,999,638 covers genotype-guided dosing of iloperidone or a specified iloperidone metabolite. Its central limitation is a determination of the patient’s KCNQ1 genotype at position 79764 of SEQ ID NO:1, followed by administration of a lower dose for the GG genotype and a higher dose for non-GG genotypes. The patent does not claim iloperidone itself, a formulation, a diagnostic test in isolation, or a specific kit.
The strongest commercial scope is directed to treatment protocols that use KCNQ1 status to select an iloperidone dose. The patent’s practical reach depends on whether a generic applicant, prescriber, health system, or diagnostic provider performs or relies on the claimed genotype-based dosing method.
What does U.S. Patent 8,999,638 claim?
The patent contains three principal independent claim frameworks:
| Claim framework |
Core subject matter |
Main limitation |
| Claim 1 |
Genotype-guided administration |
Determine KCNQ1 genotype and administer a lower or higher quantity based on GG versus non-GG |
| Claim 6 |
Expression-product characterization |
Characterize a KCNQ1 expression product and select a dose based on the corresponding genotype |
| Claim 8 |
Treatment of long QT syndrome |
Treat an individual with LQTS using a quantity determined by KCNQ1 genotype |
Claims 2 through 5 depend from claim 1. Claims 7 and 14 depend from claim 6. Claims 9, 12 and 15 depend from claim 8 or its related limitations. Claims 10 through 12 specify 24 mg/day as the second, higher quantity.
The patent is therefore a method-of-treatment patent with pharmacogenomic limitations. It is not a conventional small-molecule composition patent.
What is the scope of claim 1?
Claim 1 requires all of the following:
- A human individual.
- Administration of iloperidone or an iloperidone metabolite.
- Determination, or prior determination, of the individual’s KCNQ1 genotype.
- Testing at position 79764 of SEQ ID NO:1.
- A GG genotype associated with increased QT-prolongation risk, or a non-GG genotype not associated with that increased risk.
- Administration of a first quantity for GG and a second quantity for non-GG.
- The first quantity must be lower than the second quantity.
The “determining or having determined” language expands the claim beyond testing performed by the same actor who administers the drug. A physician, hospital, laboratory, pharmacy, diagnostic company, or third-party testing provider could perform different portions of the overall activity. That does not automatically establish infringement, but it increases the number of possible infringement theories.
Claim 1 does not specify an exact lower dose. Claims 10 through 12 add a 24 mg/day limitation for the second quantity. A protocol using 24 mg/day for non-GG patients and a lower dose for GG patients is the clearest literal match to the claim set.
What genotypes are covered by the KCNQ1 limitations?
The patent identifies GG as the increased-risk genotype and non-GG as the lower-risk category. Dependent claims 13 through 15 narrow non-GG to CC or CG.
| KCNQ1 genotype at position 79764 |
Treatment consequence under the claims |
| GG |
Lower first quantity |
| CC |
Higher second quantity under claims 13-15 |
| CG |
Higher second quantity under claims 13-15 |
| Non-GG generally |
Higher second quantity under claims 1, 6 and 8 |
The claims use genotype notation tied to a particular sequence orientation. A laboratory report using a reverse-strand designation, an alternative reference sequence, or a different SNP nomenclature could create claim-construction issues. The relevant question would be whether the reported variant corresponds to the claimed position and allele designation in SEQ ID NO:1.
How do the CYP2D6 limitations affect infringement scope?
Claim 4 adds a combined KCNQ1-CYP2D6 decision rule. It requires evaluation of specified CYP2D6 variants and links those results to the KCNQ1 genotype.
The relevant CYP2D6 variants are:
Claim 4 describes the lower-dose pathway when the patient has:
- CYP2D6G1846A genotype AA or GA, and KCNQ1 GG; or
- CYP2D6C100T genotype TT or CT, and KCNQ1 GG.
It describes the higher-dose pathway when the patient has:
- CYP2D6G1846A genotype GG; or
- CYP2D6C100T genotype CC,
together with a non-GG KCNQ1 genotype.
The claim language is narrower than claim 1 because it requires additional CYP2D6 characterization and specified genotype combinations. A product label or clinical protocol that uses only CYP2D6 results, without KCNQ1 testing, would not meet the full limitations of claim 4.
Claims 7 and 9 are also narrower than the principal KCNQ1 dosing claims. They require characterization of an expression product and determination of whether the product corresponds to one of the listed CYP2D6 polymorphisms.
What role does the 24 mg/day limitation play?
Claims 10, 11 and 12 specify 24 mg/day as the second quantity of iloperidone. These claims are narrower than the parent claims because they require:
- KCNQ1-guided dosing under claim 1, 6 or 8;
- a higher dose for the non-GG group; and
- a higher dose of 24 mg/day.
The FDA-approved Fanapt labeling identifies 24 mg/day as the maximum recommended total daily dose for adults under the standard titration regimen. The label also contains dose-adjustment provisions for patients who are poor CYP2D6 metabolizers or who receive strong CYP2D6 inhibitors.[2]
That overlap makes claims 10 through 12 commercially relevant. A generic applicant seeking approval for the same dosage strength may need to address whether its proposed labeling, prescribing information, or risk-management materials induce use of the patented genotype-guided method.
What conditions are covered by claim 5?
Claim 5 extends claim 1 to treatment of a broad group of psychiatric and related conditions, including:
- schizophrenia;
- schizoaffective disorder;
- depression;
- bipolar mania or depression;
- cardiac arrhythmia;
- Tourette’s syndrome;
- psychotic disorders;
- delusional disorder; and
- schizophreniform disorder.
The claim is not limited to schizophrenia. It also includes individuals suffering from cardiac arrhythmia, which has particular relevance because the patent’s dosing logic is directed to QT-prolongation risk.
The condition limitation applies only to claim 5. Claims 1, 6 and 8 have different structural requirements. Claim 8 is specifically directed to an individual suffering from long QT syndrome.
What does claim 8 add for long QT syndrome?
Claim 8 covers administration of iloperidone or its metabolite to a human individual with LQTS, with the dose selected according to KCNQ1 genotype.
Its principal requirements are:
- the patient has LQTS;
- the KCNQ1 genotype is determined;
- a first quantity is administered for GG; and
- a second quantity is administered for non-GG.
Unlike claim 1, claim 8 does not expressly repeat that the first quantity is lower than the second quantity in the claim text supplied. The claims should be construed as a whole, but this difference may affect infringement and validity arguments.
Claim 8 creates a distinct risk category for treatment of patients with congenital or clinically diagnosed long QT syndrome. A general QT-warning statement in a drug label would not necessarily satisfy the LQTS limitation.
What is the patent’s legal and technical character?
Patent 8,999,638 is a personalized-medicine patent. It combines:
- a known drug, iloperidone;
- a pharmacogenomic marker, KCNQ1;
- a safety phenotype, QT prolongation or LQTS; and
- a treatment decision, lower versus higher dosing.
The claims require a therapeutic act after the genetic determination. That structure distinguishes them from claims directed solely to discovering a genetic association or performing a diagnostic test.
The Federal Circuit’s decision in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd. upheld a related iloperidone pharmacogenomic treatment patent against a patent-eligibility challenge.[3] The court treated the claims as treatment methods that required a physician to determine a patient’s metabolizer status and administer a specified dose. That decision is important to the legal assessment of claim 8,999,638 because both patents use genotype information to select an iloperidone dose.
The principal validity pressure points remain:
| Issue |
Relevance to Patent 8,999,638 |
| Written description |
Whether the specification adequately supports the claimed KCNQ1 genotype-dose relationship |
| Enablement |
Whether the disclosure enables the full range of iloperidone quantities and covered patient populations |
| Anticipation |
Whether an earlier reference disclosed KCNQ1 testing and genotype-based iloperidone dosing |
| Obviousness |
Whether combining known QT-risk genetics, CYP2D6 pharmacogenomics and iloperidone treatment would have been predictable |
| Claim construction |
Meaning of position 79764, SEQ ID NO:1, non-GG, and expression-product correspondence |
| Section 101 |
Reduced risk relative to a pure diagnostic claim because the claims require treatment and dosing |
When does U.S. Patent 8,999,638 expire?
The patent issued on April 7, 2015. Its expected patent-term endpoint is April 6, 2027, based on the disclosed priority and filing history reflected in the patent record. The effective expiration date should be confirmed against the USPTO term-adjustment calculation, any terminal disclaimer, and the complete continuation chain before relying on the date for a launch or litigation decision.[1]
The patent’s term is separate from FDA regulatory exclusivity. FDA approval exclusivity for Fanapt does not extend the patent term, and expiration of an earlier iloperidone compound patent would not eliminate the method claims of Patent 8,999,638.
What is the Orange Book status of Patent 8,999,638?
Orange Book treatment depends on whether the patent is listed for an approved product and whether its claims cover an approved method of use. Method-of-use patents may be listed when they claim an approved use reflected in labeling. A patent directed to a pharmacogenomic dosing method may present a closer listing question if the FDA-approved label does not expressly instruct clinicians to test KCNQ1 genotype.
The Fanapt label emphasizes QT prolongation and CYP2D6-related dosing considerations, but it does not establish that FDA labeling directs KCNQ1 genotype testing.[2] That distinction matters:
- If the approved label does not require or recommend KCNQ1 testing, a generic applicant may argue that the patented use is not a labeled use.
- If the patent is listed, an ANDA applicant may need to submit a Paragraph IV certification or a section viii statement, depending on the scope of the listed method.
- If the patent is not listed, the patent holder may still pursue infringement under 35 U.S.C. §271(e)(2) if the proposed product and labeling are directed to the patented method.
The Orange Book listing status should be checked by patent number and by the specific Fanapt product entry before relying on a regulatory strategy.[4]
What Paragraph IV and generic-entry risks exist?
A generic applicant could challenge the patent through a Paragraph IV certification based on:
- lack of anticipation;
- obviousness;
- inadequate written description;
- lack of enablement;
- indefiniteness of the sequence-position and genotype language;
- noninfringement based on a label that omits KCNQ1 testing; or
- a section viii carveout for any patented use not included in the generic label.
The most important generic-label question is whether the proposed labeling encourages the claimed conduct. A label that merely warns about QT prolongation may not induce KCNQ1-guided dose selection. A label that expressly recommends genetic testing and specifies lower dosing for GG patients would create materially higher infringement exposure.
The patent does not claim a generic iloperidone product, tablet strength, excipient system, or manufacturing process. A generic manufacturer could therefore face a narrower patent issue than under a composition or formulation patent, but label design would become central.
What formulation and manufacturing patents compete with this patent?
Patent 8,999,638 does not claim:
- immediate-release or extended-release tablets;
- particle size;
- salt or polymorph forms;
- excipients;
- dissolution profiles;
- packaging;
- synthetic intermediates; or
- manufacturing processes.
Those categories must be analyzed separately from the pharmacogenomic estate. A generic launch can be blocked or delayed by a formulation or process patent even if the generic label avoids the KCNQ1 dosing method. Conversely, freedom to practice a formulation patent does not establish freedom to practice the claimed treatment method.
The relevant patent landscape should therefore be divided into four layers:
| Layer |
Typical protection |
Relationship to 8,999,638 |
| Compound patents |
Iloperidone molecule and chemical variants |
Separate from genotype-guided treatment |
| Formulation patents |
Tablet composition, release profile, stability |
Separate technical barrier |
| Method-of-use patents |
Schizophrenia, psychosis, QT-risk management |
Potentially overlapping commercial barrier |
| Pharmacogenomic patents |
KCNQ1 and CYP2D6 testing with dose selection |
Core estate represented by 8,999,638 |
How strong is the patent estate for iloperidone?
Patent 8,999,638 has meaningful scope in a narrow clinical pathway but limited scope against an ordinary generic launch. Its strongest features are:
- a concrete treatment step;
- a defined genetic marker;
- a binary dosing rule;
- specific dependent claims for 24 mg/day; and
- a treatment context linked to QT risk.
Its limitations are equally important:
- no composition claim;
- no diagnostic-kit claim;
- no assay-platform claim;
- no exact lower dose in the independent claims;
- dependence on a genotype designation tied to a sequence identifier; and
- potential separation between the patented use and the FDA-approved label.
The estate is therefore more useful for targeted litigation or licensing than for blocking all iloperidone competition.
Which companies are likely to face the greatest risk?
The highest-risk parties are those that:
- market iloperidone with labeling that recommends pharmacogenomic testing;
- promote treatment protocols for patients with LQTS or elevated QT risk;
- operate clinical decision-support systems that automatically select iloperidone doses from KCNQ1 results; or
- license a diagnostic service linked to iloperidone prescribing.
A conventional ANDA applicant that omits KCNQ1 testing and does not encourage the patented dosing method has a stronger noninfringement position. The patent is less likely to block a product whose labeling follows the ordinary Fanapt regimen without the claimed genotype-based dose differentiation.
What licensing and settlement issues matter?
A license should address more than the patent number. Key terms would include:
- permitted KCNQ1 testing methods;
- use of CYP2D6 data;
- approved and off-label indications;
- commercial versus investigator-sponsored use;
- diagnostic-provider rights;
- sublicensing;
- patent-term coverage through 2027;
- royalty treatment for drug sales versus test sales; and
- settlement restrictions on generic labeling.
A settlement that permits an early generic launch but prohibits KCNQ1-directed promotion could preserve the patent holder’s method-of-use position while reducing litigation cost. The commercial value of such a settlement would depend on whether KCNQ1 testing is used in routine practice.
Key Takeaways
- Patent 8,999,638 covers genotype-guided administration of iloperidone or a specified metabolite.
- The core distinction is lower dosing for KCNQ1 GG patients and higher dosing for non-GG patients.
- Claims 10 through 12 identify 24 mg/day as the higher dose.
- CYP2D6 limitations narrow the claim set and require additional genotype characterization.
- Claim 8 specifically addresses patients with long QT syndrome.
- The patent does not claim iloperidone, a formulation, a diagnostic kit, or a manufacturing process.
- The expected patent-term endpoint is April 6, 2027, subject to the official USPTO term calculation.
- Generic litigation would likely focus on label-induced infringement, obviousness, written description, enablement, and the meaning of the KCNQ1 sequence-position limitation.
- The patent is more significant as a targeted pharmacogenomic method patent than as a complete barrier to generic iloperidone entry.
FAQs
Does Patent 8,999,638 cover every iloperidone prescription?
No. The prescription must use the claimed KCNQ1 genotype-based dose-selection process, or satisfy the narrower expression-product, CYP2D6, LQTS or 24 mg/day limitations.
Does testing CYP2D6 alone infringe Patent 8,999,638?
Generally no, based on the supplied claims. The principal claims require KCNQ1 characterization. CYP2D6 testing is an added limitation in certain dependent claims.
Can a generic manufacturer avoid the patent by omitting KCNQ1 testing from its label?
Potentially. A label that does not encourage KCNQ1 testing or genotype-based dose selection may support a noninfringement or section viii position, although the complete product, labeling and litigation record would control.
Is the KCNQ1 genotype itself patented?
No. The claims supplied do not claim the naturally occurring genotype in isolation. They claim a treatment method that uses the genotype to select an iloperidone dose.
Does the patent cover iloperidone metabolites?
Yes. Claims 1, 3, 6 and 8 include iloperidone or a metabolite thereof. Claim 3 specifically identifies 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanol.
References
- U.S. Patent No. 8,999,638. (2015). Methods of treating patients with iloperidone based on genetic polymorphisms. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2017). Fanapt (iloperidone) prescribing information. Novartis Pharmaceuticals Corporation.
- Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd., 887 F.3d 1117 (Fed. Cir. 2018).
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
